SCHEMBL4420765

SCHEMBL4420765

COC(=O)/C=C(\C)CC/C=C(\C)CCC1OC1(C)C

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LSS P48449 10/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119016 1.00 LSS (0.58) LSS
SCHEMBL1704748 1.00 LSS (0.58) LSS
SCHEMBL727892 0.93 LSS (0.51) LSS
SCHEMBL119229 0.88 LSS (0.46) LSS
SCHEMBL7191948 0.88 LSS (0.46) LSS
SCHEMBL8767769 0.88 LSS (0.46) LSS
SCHEMBL8767763 0.88 LSS (0.46) LSS
SCHEMBL7191953 0.88 LSS (0.46) LSS
SCHEMBL4435563 0.86 LSS (0.56) LSS
SCHEMBL1705558 0.86 LSS (0.56) LSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022166842-A1 COMPOSITION COMPRISING BENZYLAMINE ACARICIDE AND USE THEREOF 山东康乔生物科技有限公司 2022-08-11 WO claimed
US-20060035873-A1 Methods for inducing apolipoprotein e secretion ILEX PRODUCTS, INC. 2006-02-16 US claimed
EP-1019059-A4 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION UNIV CALIFORNIA (US) 2004-01-14 EP claimed
JP-2001509165-A 2001-07-10 JP claimed
US-6187814-B1 BY TOPICALLY AN FARNESOID X-ACTIVATED RECEPTOR (FXR) ACTIVATOR SELECTED FROM FARNESAL, ALKYL FARNESYL ETHER, ALKYL FARNESOATE, AND 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID, ALKYL ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-02-13 US claimed
WO-2000049992-A2 USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-08-31 WO claimed
EP-1019059-A1 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-07-19 EP claimed
US-6071955-A TREATING TERRESTRIAL MAMMALIAN SUBJECT SUFFERING FROM A CONDITIONS OF ACNE AND ACNEIFORM CONDITIONS BY ADMINISTERING 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID METHYL ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-06-06 US claimed
WO-1998032444-A1 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-30 WO claimed
CN-122036637-A Polymorphs 先正达农作物保护股份公司 2026-05-15 CN disclosed
US-20260020567-A1 CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE FUNGICIDES SYNGENTA CROP PROTECTION AG (CH) 2026-01-22 US disclosed
US-20250241304-A1 FUNGICIDAL COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2025-07-31 US disclosed
CN-120019749-A Spraying bias flow aid 禾大国际股份公开有限公司 2025-05-20 CN disclosed
CN-119998270-A Microbiocidal pyrazole derivatives 先正达农作物保护股份公司 2025-05-13 CN disclosed
EP-1019059-A1 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-07-19 EP disclosed
US-6071955-A TREATING TERRESTRIAL MAMMALIAN SUBJECT SUFFERING FROM A CONDITIONS OF ACNE AND ACNEIFORM CONDITIONS BY ADMINISTERING 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID METHYL ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-06-06 US disclosed
US-6071955-A TREATING TERRESTRIAL MAMMALIAN SUBJECT SUFFERING FROM A CONDITIONS OF ACNE AND ACNEIFORM CONDITIONS BY ADMINISTERING 7-METHYL-9-(3,3-DIMETHYLOXIRANYL)-3-METHYL-2,6-NONADIENOIC ACID METHYL ESTER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-06-06 US disclosed
US-6060515-A TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-09 US disclosed
US-6005086-A WHEREIN SAID POLYPEPTIDE IS A NUCLEAR RECEPTOR AND IS RESPONSIVE TO THE PRESENCE OF FARNESOID TO REGULATE THE TRANSCRIPTION OF ASSOCIATED GENE(S) THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1999-12-21 US disclosed
WO-1998032444-A1 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260020567-A1 CRYSTALLINE FORMS OF 1,2,4-OXADIAZOLE FUNGICIDES CYP51A1, CYP4B1, CYP8B1 LSS 67/4885
US-20250241304-A1 FUNGICIDAL COMPOUNDS CYP1B1, CYP51A1, CYP1A1 LSS 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.